Evidence map›Paper›PMID 32375802›Full record

ArticleBMC veterinary research2020

Expression of HIF-1α and VEGF in feline mammary gland carcinomas: association with pathological characteristics and clinical outcomes.

Bo Chen, Susanne Je-Han Lin, Wen-Ta Li, Hui-Wen Chang, Victor Fei Pang, Pei-Yi Chu, Chin-Cheng Lee, Hiroyuki Nakayama, Ching-Ho Wu, Chian-Ren Jeng

Open access · goldAbstract read
In one paragraph

Article in BMC veterinary research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.2field-weighted citation impact, top 58% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Bo ChenGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
Susanne Je-Han LinGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
Wen-Ta LiGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
Hui-Wen ChangGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
Victor Fei PangGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan.
Pei-Yi ChuDepartment of Pathology, Show Chwan Memorial Hospital, Changhua, Taiwan.
Chin-Cheng LeeDepartment of Pathology, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan.
Hiroyuki NakayamaDepartment of Pathology, The University of Tokyo, Tokyo, Japan.
Ching-Ho WuInstitute of Veterinary Clinical Science, School of Veterinary Medicine, National Taiwan University, Taipei, Taiwan. chinghowu@ntu.edu.tw.
Chian-Ren JengGraduate Institute of Molecular and Comparative Pathobiology, National Taiwan University, Taipei, Taiwan. crjeng@ntu.edu.tw.ORCID http://orcid.org/0000-0003-3941-6276
National Taiwan University · TWChang Bing Show Chwan Memorial Hospital · TWThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe microenvironment within solid malignant tumors, including feline mammary gland carcinomas (FMGCs), is commonly hypoxic, possibly due to the lack of functional blood vessels in rapidly proliferating neoplastic tissue. Malignant cells can undergo genetic and adaptive changes that prevent them from dying due to oxygen deprivation through expressions of hypoxia-inducible factor 1 alpha (HIF-1α) and vascular endothelial growth factor (VEGF). Therefore, HIF-1α and VEGF are ideal biomarkers for cancer therapy and prognostic evaluation. The aims of this study were to evaluate the expression of HIF-1α and VEGF in feline mammary carcinomas and analyze their correlations with clinical and pathological factors, such as clinical stage, histologic grading, regional metastasis, and overall survival rate.

resultsParaffin-embedded tissue samples collected from 72 cats with FMGCs were retrospectively studied. Histologic pattern and histologic grading (Elston and Ellis grading system) of these FMGCs were determined. Our data indicated that grade II tubulopapillary carcinomas (43/72, 59.7%) prevailed in this study, and most FMCGs showed apparent necrosis, squamous metaplasia, and intratumoral stromal response. According to the results of immunohistochemical (IHC) stainings performed in tissue microarrays (TMAs), HIF-1α and VEGF overexpressions were respectively noted in 69.4% (50/72) and 77.8% (56/72) of FMGC cases. Chi-square test showed no correlation of HIF-1α overexpression with clinical and pathological factors. VEGF overexpression was significantly correlated with histologic pattern (p = 0.021), stromal response (p = 0.048), squamous metaplasia (p = 0.001), and lymphovascular invasion (p = 0.007). However, neither HIF-1α nor VEGF overexpression was correlated with histologic grading and metastasis. Of 38 cats with 1-year follow-up, IHC stainings of HIF-1α and VEGF were performed on whole tissue sections. The results showed that overexpression of HIF-1α was significantly correlated with the overall survival rate (p < 0.05) (log-rank test), whereas there was no significant correlation between VEGF overexpression and overall survival rate.

conclusionsThis study suggests that the overexpression of HIF-1α may indicate poor prognosis/overall survival rate in cats with FMGCs. Developing compounds that inhibit HIF-1α may be a potential approach to FMGC treatment.

Indexed as

AnimalsCarcinomaCat DiseasesCatsFemaleGene Expression Regulation, NeoplasticHypoxia-Inducible Factor 1, alpha SubunitMaleMammary Neoplasms, AnimalPrognosisRetrospective StudiesVascular Endothelial Growth FactorsHypoxia-Inducible Factor 1, alpha SubunitVascular Endothelial Growth FactorsFelineHypoxia-inducible factor 1 alpha (HIF-1α)Mammary gland carcinomaVascular endothelial growth factor (VEGF)

Identifiers

PMID32375802
PMCPMC7204310
OpenAlexW3021906011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.